Anabolic Agents and the Body: The Pharmacology of Performance, Without Myths - Episode 7: Anabolic Agents and the Lipid Profile

When anabolic agents and cardiovascular health are discussed, blood pressure and the heart usually take center stage. The lipid profile receives less attention because it does not appear in the mirror and, in most cases, does not produce symptoms when it starts to deteriorate. That is precisely why it can be one of the most dangerous parts of the problem: the change may exist for a long time before the athlete feels anything.

Anabolic-androgenic agents can alter HDL cholesterol, LDL cholesterol, triglycerides and other components of lipoprotein metabolism. In some settings, apolipoproteins and vascular function can also change. These abnormalities are not cardiovascular events by themselves, but they can shift the biological environment toward greater atherosclerotic risk and, over time, cardiovascular disease.

1. What Is the Lipid Profile?

A routine lipid profile usually includes total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Each marker describes a different part of lipid transport and metabolism. The problem begins when these numbers are treated as isolated scores rather than as components of a larger metabolic and cardiovascular picture.

Cholesterol is required for cell membranes and steroid-hormone synthesis, but the body has to transport it between tissues. Lipoproteins perform that transport. Some particles deliver cholesterol to tissues, while others participate in reverse cholesterol transport. From an atherosclerotic-risk perspective, however, the number and characteristics of atherogenic particles matter more than total cholesterol alone.

2. HDL: Why a Reduction Matters, but Should Not Be Oversimplified

HDL is popularly called the “good cholesterol.” The phrase is useful for beginners but too simple to capture the biology. HDL participates in reverse cholesterol transport and has multiple biological functions, but the HDL-cholesterol concentration alone does not represent the entire protective capacity of HDL biology.

With anabolic-androgenic exposure, reduced HDL is one of the most commonly discussed lipid changes. Some agents, particularly certain oral preparations, can produce pronounced changes. The problem is not merely that one number falls on a lab report. Very low HDL can appear alongside increases in atherogenic particles and unfavorable changes in vascular function.

3. LDL: The Particles That Matter in Atherosclerosis

LDL is often called “bad cholesterol,” but biologically it is more accurate to discuss the particles that transport cholesterol and may contribute to lipoprotein retention in the arterial wall. Over time, greater exposure to atherogenic particles can promote initiation and progression of atherosclerosis.

In sport, a common problem is the contrast between visible performance and invisible risk. An athlete can have low body fat, large muscle mass and excellent conditioning while LDL or the number of atherogenic particles is unfavorable. Physical fitness does not cancel lipoprotein biology.

4. Triglycerides: Energy in the Blood

Triglycerides are the major storage form of fat energy and circulate in blood within lipoprotein particles. Elevated levels can result from many causes, including diet, insulin resistance, excess calorie intake, alcohol, metabolic disease and medications. In an athlete's lipid assessment, triglycerides should be interpreted together with the other markers and the metabolic context.

Anabolic agents do not all produce the same lipid pattern. Some exposures may affect HDL most strongly, while others influence several components at once. Therefore, the statement “my triglycerides are fine, so my lipid profile is fine” is not enough to describe cardiovascular risk.

5. Apolipoproteins and Why Particle Number Can Matter

Apolipoprotein B, or ApoB, is the principal protein component of several atherogenic lipoproteins. Because of that, ApoB can provide a useful estimate of the number of circulating atherogenic particles and may complement the information provided by LDL cholesterol.

Not every athlete automatically needs ApoB or an expanded lipid panel, but the concept is important: two people can have the same LDL cholesterol and still have different numbers of atherogenic particles. In some clinical situations, that difference can meaningfully change risk assessment.

6. How Can Anabolic Agents Alter Lipids?

The effects depend on the compound, structure, dose, duration and combination of agents. Some androgens can strongly suppress HDL and alter LDL through changes in hepatic lipoprotein metabolism. Oral compounds with specific structural modifications can have particularly unfavorable lipid effects.

At the same time, it is incorrect to reduce the issue to the idea that any non-aromatizing substance is “good for cholesterol.” Lack of aromatization describes one metabolic pathway, not a cardiovascular safety certificate. The lipid profile reflects the interaction of compound structure, liver metabolism, hormone signaling, lipoprotein handling and the rest of the metabolic environment.

7. Why Are Some Oral Forms Particularly Problematic?

Some orally active anabolic steroids with 17α-alkylation have been associated with more severe lipid disturbances than many injectable preparations. The mechanisms are complex and involve hepatic metabolism and regulation of lipoproteins. This is one reason why route of administration and chemical structure are not secondary details when cardiovascular risk is discussed.

In practice, labels such as “oral,” “injectable,” “dry,” “wet,” “mild” or “hard” do not by themselves tell you the magnitude of the effect on the lipid profile. Laboratory measurements show the direction in which the organism has moved.

8. Atherosclerosis: The Process That Builds Quietly

Atherosclerosis is a chronic process in which atherogenic lipoprotein particles enter and become retained within the arterial wall, triggering inflammation and vascular remodeling. It does not appear in a week and it does not disappear immediately after an athlete stops a drug.

That is where perspective becomes important. The athlete sees the present: performance, body weight, vascularity and training capacity. Atherosclerosis works on a different time scale. Repeatedly unfavorable lipid exposure over months and years can contribute to a process that becomes clinically visible much later.

9. A Good Lipid Profile Does Not Mean Zero Risk

Even a normal lipid profile does not mean cardiovascular risk is zero. Hypertension, smoking, diabetes, insulin resistance, family history, kidney disease, sleep apnea and other variables can materially alter total risk.

Athletes also face the problem of measurements being taken under special conditions. Highly restrictive diets, dehydration, rapid weight changes and timing of blood collection can temporarily affect some values. Correct interpretation therefore requires repetition and context, not a reaction to a single number.

10. Which Tests Are Relevant?

In a clinical context, a baseline assessment may include total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Depending on the overall risk profile and the physician's recommendation, ApoB, non-HDL cholesterol and other metabolic assessments may also be useful.

The trend is what matters. One isolated value says less than the evolution of the lipid profile before, during and after a period of exposure. For someone using androgens, medical monitoring should mean clinical interpretation, not simply collecting PDFs of laboratory reports.

11. What Happens After Exposure Stops?

Some lipid abnormalities associated with androgen exposure can improve after exposure is reduced or stopped, but the magnitude and speed of recovery vary. Compound, duration, dose, diet, genetics and baseline metabolic health all matter.

More importantly, later normalization of HDL or LDL does not automatically erase a previous atherogenic exposure. Cardiovascular risk has to be viewed longitudinally, and established atherosclerotic disease is not equivalent to a simple reversible laboratory abnormality.

12. Why Does This Matter in Strongman?

Modern Strongman combines high body mass, extreme efforts, large acute blood-pressure responses and, in some athletes, pharmacological exposure. In such a system, an unfavorable lipid profile is not a footnote. It is one of the components that can alter long-term risk while the athlete is optimizing short-term performance.

The issue is even more important because lipids do not tell you that something hurts. An athlete can sleep well, eat a great deal, lift enormous weights and finish a contest without unusual cardiac sensations while lipoprotein metabolism is already moving in an unfavorable direction.

Conclusion: Cholesterol Does Not Appear on Instagram, but It Becomes Part of Biological History

The lipid profile is one of the most important bridges between performance pharmacology and cardiovascular risk. Anabolic agents can lower HDL, raise LDL or other atherogenic particles, and alter the biological environment in which atherosclerosis begins and progresses.

For the athlete, the central lesson is that performance and cardiovascular health are not two graphs that must move in the same direction. You can become bigger, stronger and faster while the lipid profile worsens. Because the change is invisible, it has to be measured.

In performance pharmacology without myths, HDL is not simply “good karma,” LDL is not the only villain, and one laboratory panel cannot predict the future. What matters is the combination of atherogenic particles, blood pressure, metabolism, cardiac structure, lifestyle, genetics and cumulative exposure. That is the adult version of the cholesterol discussion.

References

Baggish, A. L., Weiner, R. B., Kanayama, G., Hudson, J. I., Lu, M. T., Hoffmann, U., & Pope, H. G. Jr. (2017). Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use. Circulation.

Nieschlag, E., & Vorona, E. (2015). Medical consequences of doping with anabolic androgenic steroids: effects on reproductive and cardiovascular systems. European Journal of Endocrinology.

Feingold, K. R., & Grunfeld, C. Endotext. Introduction to Lipids and Lipoproteins. NCBI Bookshelf.

Mach, F., et al. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal.

Ference, B. A., et al. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. European Heart Journal.

Sniderman, A. D., et al. Literature on apolipoprotein B and atherogenic particle burden.